We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


IDT Expands Oligonucleotide Manufacturing in Singapore

Want a FREE PDF version of this news story?

Complete the form below and we will email you a PDF version of "IDT Expands Oligonucleotide Manufacturing in Singapore"

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.
Read time:

Integrated DNA Technologies (“IDT”), the global leader in custom nucleic acid synthesis, has entered into a definitive agreement to acquire the oligonucleotide synthesis business of AITbiotech Pte. Ltd. in Singapore (“AITbiotech”). With this acquisition, IDT expands its customer base across Southeast Asia making it possible for these additional customers to now have access to its broad range of products for genomic applications. AITbiotech will continue operations in its other core business areas. 

Dr. Joseph A. Walder, IDT founder and chief executive officer, commented, “With this purchase, we further expand our presence in the region and look forward to welcoming AITbiotech customers to IDT. The entire Singapore scientific research market can now benefit from IDT’s unrivalled manufacturing capabilities, design expertise and fast turnaround times.”

Alex Thian, chief executive officer of AITbiotech, added, “We share a commitment with IDT to produce consistently high-quality oligos and to provide personal service for customers. Both companies are working diligently to facilitate a smooth transition of the business and we are excited to begin this next chapter in the ever expanding Singapore market.”